Anthropic, a leading AI firm, has launched a tokenized pre-IPO asset on the Solana blockchain via CoinGecko, priced around $984.87. This token reflects a speculative market cap of about $7.56 million ahead of Anthropic's confidential IPO filing with Nasdaq. The asset's trading volume of $274,000 on October 19, 2026, indicates growing investor interest and market confidence in Anthropic's future valuation. Investors should watch for updates on the official IPO filing and Nasdaq listing for clearer valuation insights.
Anthropic's tokenized pre-IPO asset on Solana provides context for cryptocurrency market activity. For readers following crypto markets, here is Pluang's snapshot as of Oct 19, 2026 15:02 WIB: out of 50 major cryptocurrencies, 41 rose and 8 fell. Solana (SOL) rose 2.51% to Rp1.898.186 with a typical hold time of 71 days and a slightly higher sell order activity at 52%. Chainlink (LINK) also gained 2.33% to Rp220.262, while Enjin Coin (ENJ) declined 2.15% to Rp491, showing the widest sell pressure at 95%.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
